1-8 of 8
Daniel A. Pollyea
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies

Mark A. Dawson, Gautam Borthakur, Brian J.P. Huntly, Anastasios Karadimitris, Adrian Alegre, Aristeidis Chaidos, Dan T. Vogl, Daniel A. Pollyea, Faith E. Davies, Gareth J. Morgan, Jacob L. Glass, Manali Kamdar, Maria-Victoria Mateos, Natalia Tovar, Paul Yeh, Regina García Delgado, Faisal Basheer, Ludovica Marando, Paolo Gallipoli, Anastasia Wyce, Anu Shilpa Krishnatry, Olena Barbash, Evi Bakirtzi, Geraldine Ferron-Brady, Natalie O. Karpinich, Michael T. McCabe, Shawn W. Foley, Thierry Horner, Arindam Dhar, Brandon E. Kremer, Michael Dickinson
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (4): 711–722.
https://doi.org/10.1158/1078-0432.CCR-22-1284
Published: 16 February 2023
View article titled, A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies
Open the PDF for A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies in another window
Includes: Supplementary data
Journal Articles

Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine

Daniel A. Pollyea, Keith W. Pratz, Andrew H. Wei, Vinod Pullarkat, Brian A. Jonas, Christian Recher, Sunil Babu, Andre C. Schuh, Monique Dail, Yan Sun, Jalaja Potluri, Brenda Chyla, Courtney D. DiNardo
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (24): 5272–5279.
https://doi.org/10.1158/1078-0432.CCR-22-1183
Published: 15 December 2022
View article titled, Outcomes in Patients with Poor-Risk Cytogenetics with or without <em>TP53</em> Mutations Treated with Venetoclax and Azacitidine
Open the PDF for Outcomes in Patients with Poor-Risk Cytogenetics with or without <em>TP53</em> Mutations Treated with Venetoclax and Azacitidine in another window
Includes: Supplementary data
Journal Articles

Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations

Daniel A. Pollyea, Courtney D. DiNardo, Martha L. Arellano, Arnaud Pigneux, Walter Fiedler, Marina Konopleva, David A. Rizzieri, B. Douglas Smith, Atsushi Shinagawa, Roberto M. Lemoli, Monique Dail, Yinghui Duan, Brenda Chyla, Jalaja Potluri, Catherine L. Miller, Hagop M. Kantarjian
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (13): 2753–2761.
https://doi.org/10.1158/1078-0432.CCR-21-3467
Published: 01 July 2022
View article titled, Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and <em>IDH1/2</em> Mutations
Open the PDF for Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and <em>IDH1/2</em> Mutations in another window
Includes: Supplementary data
Journal Articles

Project 2025: Proposals for the Continued Success of Drug Development in Acute Myeloid Leukemia

Daniel A. Pollyea, John Barrett, Courtney D. DiNardo, Laura C. Michaelis, Gail J. Roboz, Robert Q. Le, Kelly J. Norsworthy, R. Angelo de Claro, Marc R. Theoret, Richard Pazdur
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (5): 816–820.
https://doi.org/10.1158/1078-0432.CCR-21-2124
Published: 01 March 2022
View article titled, Project 2025: Proposals for the Continued Success of Drug Development in Acute Myeloid Leukemia
Open the PDF for Project 2025: Proposals for the Continued Success of Drug Development in Acute Myeloid Leukemia in another window
Journal Articles

Next-Generation Sequencing and Eating of the Tree of Knowledge

Daniel A. Pollyea
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (23): 5790–5791.
https://doi.org/10.1158/1078-0432.CCR-18-1835
Published: 03 December 2018
View article titled, Next-Generation Sequencing and Eating of the Tree of Knowledge
Open the PDF for Next-Generation Sequencing and Eating of the Tree of Knowledge in another window
Journal Articles

Targeting the IDH2 Pathway in Acute Myeloid Leukemia

Maria L. Amaya, Daniel A. Pollyea
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (20): 4931–4936.
https://doi.org/10.1158/1078-0432.CCR-18-0536
Published: 15 October 2018
View article titled, Targeting the <em>IDH2</em> Pathway in Acute Myeloid Leukemia
Open the PDF for Targeting the <em>IDH2</em> Pathway in Acute Myeloid Leukemia in another window
Journal Articles

Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS

Michael R. Savona, Daniel A. Pollyea, Wendy Stock, Vivian G. Oehler, Mark A. Schroeder, Jeffrey Lancet, James McCloskey, Hagop M. Kantarjian, Weidong Wendy Ma, M. Naveed Shaik, A. Douglas Laird, Mirjana Zeremski, Ashleigh O'Connell, Geoffrey Chan, Jorge E. Cortes
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (10): 2294–2303.
https://doi.org/10.1158/1078-0432.CCR-17-2824
Published: 14 May 2018
View article titled, Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS
Open the PDF for Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS in another window
Includes: Supplementary data
Journal Articles

Tyrosine Kinase Inhibition in Leukemia Induces an Altered Metabolic State Sensitive to Mitochondrial Perturbations

Francesca Alvarez-Calderon, Mark A. Gregory, Catherine Pham-Danis, Deborah DeRyckere, Brett M. Stevens, Vadym Zaberezhnyy, Amanda A. Hill, Lelisa Gemta, Amit Kumar, Vijay Kumar, Michael F. Wempe, Daniel A. Pollyea, Craig T. Jordan, Natalie J. Serkova, Douglas K. Graham, James DeGregori
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (6): 1360–1372.
https://doi.org/10.1158/1078-0432.CCR-14-2146
Published: 12 March 2015
View article titled, Tyrosine Kinase Inhibition in Leukemia Induces an Altered Metabolic State Sensitive to Mitochondrial Perturbations
Open the PDF for Tyrosine Kinase Inhibition in Leukemia Induces an Altered Metabolic State Sensitive to Mitochondrial Perturbations in another window
Includes: Supplementary data